Pneumococal vaccine

Morbidity and lethality rates in pneumococal infections are higher among children with underlying diseases associated with restricted or absent splenic function. Vaccination with polyvalent vaccine is indicated in all children who are more than 2 years old and who have been splenectomized or have a congenital asplenia. Since protection by vaccination is 80% only, we combine the vaccination with penicillin prophylaxis for at present at least three to five years after splenectomy and draw the express attention of parents and family physicians to the limited nature of protection afforded by vaccination...

After an acute attack of otitis media 827 children aged 3 months to 6 years were assigned randomly to receive either 14-valent pneumococcal polysaccharide vaccine or a control vaccine (Haemophilus influenzae type b capsular polysaccharide). In children older than 6 months serum antibody responses to most of the vaccine polysaccharides were satisfactory. The response to type 6A was poor. Correspondingly, no clinical protection was seen below 6 months of age or against otitis media caused by group 6 pneumococci...

The bacteriologic findings of 1205 episodes of pneumococcal otitis media are analyzed. Capsular types 6, 14, 19 and 23 have been found to account for more than half the initial and subsequent infections of the middle ear. Initial infection has been shown to be related to age, and recurrent infection with pneumococci of heterologous capsular types has been found to occur most often within six months of the initial attack. Nasopharyngeal carriage of the pneumococcal types most frequently causing otitis media may occur without causing infection, may antedate infection by as long as 13 months and may persist after infection for as long as 30 months...